Clinical trial
Atomoxetine in Adolescents With Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorder (SUD)
NCT00218322 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Atomoxetine in Adolescents With Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorder (SUD)
- Lead sponsor
- Massachusetts General Hospital
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- September 30, 2004
- Completion date
- April 30, 2006
- Enrollment
- 108 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.